This is a totally different scale and you need a bit more patience, you need a bit more time. In the end we will deliver the same outcome: we will pay off the debt and we will improve margins, the Street is wanting to see quarter-by-quarter that we can actually integrate this business, that we haven't over-stretched and can pay down debt.

Chief Executive Flemming Ornskov

Categorized in : Health News

To make a comparison from Zydus to all the other ones, is I think... by Chief Executive Flemming Ornsk...

To make a comparison from Zydus to all the other ones, is I think a stretch of the imagination.

Chief Executive Flemming Ornskov

We have invested beyond just the quarter (...) in growth for the full year and for the coming years, we actually upgraded EPS guidance for the year. I don't think you do that if you don't have increased confidence in your outlook and you have your expenses under full control.

Chief Executive Flemming Ornskov

We have a strategy of becoming a leading global biotech company focused on rare disease and select other speciality areas and M&A small or large could be part of that.

Chief Executive Flemming Ornskov

We are firing on all cylinders, we are very satisfied with the pr... by Chief Executive Flemming Ornsk...

We are firing on all cylinders, we are very satisfied with the progress we've made.

Chief Executive Flemming Ornskov

We look at the prescription trends and take that as a great indicator for the unmet need for this condition.

Chief Executive Flemming Ornskov

The designation is normally given if a compound potentially would bring significant progress either in terms of safety or efficacy, so we take that as a positive sign.

Chief Executive Flemming Ornskov

We have excellent momentum and we are gaining even further moment... by Chief Executive Flemming Ornsk...

We have excellent momentum and we are gaining even further momentum.

Chief Executive Flemming Ornskov